The pharmacokinetics of pergolide in Parkinson's disease

@article{Blin2003ThePO,
  title={The pharmacokinetics of pergolide in Parkinson's disease},
  author={Olivier Blin},
  journal={Current Opinion in Neurology},
  year={2003},
  volume={16},
  pages={S9–S12},
  url={https://api.semanticscholar.org/CorpusID:1734931}
}
Pergolide has a long half-life of about 21 h; this has interesting implications, as it should produce a more physiological or continuous stimulation of dopamine receptors, avoiding or delaying the induction of dyskinesia.
View on Wolters Kluwer
ncbi.nlm.nih.gov
26 Citations
Highly Influential Citations
1
Background Citations
14
Methods Citations
2

26 Citations

Single-dose oral pharmacokinetics of pergolide mesylate in healthy adult mares.

The pharmacokinetics of pergolide are described in a small group of relatively young, healthy mares with the objective of generating data on which to base larger studies in the future, and to make definitive dosing recommendations to clinicians.

Pharmacokinetic Optimisation in the Treatment of Parkinson’s Disease

In general, initial dopamine receptor agonist monotherapy is associated with poorer motor performance and lower incidence of motor complications compared with levodopa, and CDS can be approached by optimising the use of dopaminergic drugs based on pharmacokinetic data.

Pharmacokinetics of pergolide after intravenous administration to horses.

With an elimination half-life of approximately 6 hours, twice-daily dosing may be more appropriate than once- daily dosing to reduce peak-trough fluctuation in pergolide concentrations.

PHARMACOKINETICS OF PERGOLIDE IN NORMAL MARES

Horses appear to absorb and eliminate pergolide more rapidly than previously expected and the dosing strategies of per golide may need to be altered.

Translational pharmacology of intranasal administration of dopamine receptor agonists and antagonists

There is a need for refined animal models and biomarkers to provide insight into brain target site PK in relation to dopaminergic brain activity, to be extrapolated to the human situation using translational pharmacology approaches.

Equine Pergolide Toxicity: A Case Series

Two patients experienced similar clinical presentations resulting from their unintentional pergolide ingestions and case reports of human toxicity may assist with anticipating the clinical course and guiding medical decision-making.

Pharmacokinetic Changes of Psychotropic Drugs in Patients with Liver Disease

Kinetic studies for centrally acting drugs with predominant hepatic metabolism should be carried out in patients with liver disease to allow precise dose recommendations for enhanced patient safety, if information from clinical studies is lacking.

An update on the pharmacogenetic considerations when prescribing dopamine receptor agonists for Parkinson’s disease

This review describes and updates the clinical impact of genetic factors associated with the efficacy and adverse drug reactions related to common medications used to treat Parkinson’s disease.

Pharmacological therapy of Parkinson's disease: current options and new avenues.

The aim of this review is to summarize the features of drugs currently used in the pharmacotherapy of Parkinson's disease, with a look at their beneficial effects and limitations.

Dopamine Receptors and Parkinson's Disease

Parkinson's disease (PD) is a progressive extrapyramidal motor disorder. Pathologically, this disease is characterized by the selective dopaminergic (DAergic) neuronal degeneration in the substantia…

10 References

Physiologic disposition of pergolide

Pergolide, a synthetic ergoline, is a potent long‐acting dopaminergic drug effective in Parkinson's disease and amenorrhea‐galactorrhea, and radioactivity was present in plasma and red blood cells but could not be displaced by other drugs that are also bound or by possible metabolites of pergolides.

Sensitive, specific radioimmunoassay for quantifying pergolide in plasma.

The radioimmunoassay has performed acceptably for > 2 years during toxicology studies with rats and rhesus monkeys and in clinical studies involving patients with Parkinson disease, and is considered a valid method for quantifying therapeutic concentrations of pergolide in plasma.

Pharmacology of dopamine agonists in the treatment of Parkinson’s disease

Continuous administration of long-acting dopamine agonists may reverse the priming process initiated by l-dopa, markedly decreasing dyskinesia intensity with a minimal loss of antiparkinsonian activity, at least in MPTP-treated primates.

Dopamine agonist activities of pergolide, its metabolites, and bromocriptine as measured by prolactin inhibition, compulsive turning, and stereotypic behavior.

Bromocriptine, while possessing some dopamine agonist activity at higher doses in some of these animal models, was much less potent than either pergolide or its two dopaminergic metabolites.

L-Dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations

These results show for the first time that chronic oral L-dopa administration can provoke dyskinesias in primates independently of nigrostriatal damage, and that this effect is dose related.

Effect of pulsatile administration of levodopa on dyskinesia induction in drug‐naïve MPTP‐treated common marmosets: Effect of dose, frequency of administration, and brain exposure

Increasing pulsatile exposure of brain to L‐dopa by preventing its peripheral breakdown also increases dyskinesia induction, which was initially more severe than occurred with L‐Dopa alone.

The role of dopamine agonists in early Parkinson's disease

The traditional role of dopamine agonist monotherapy is reviewed and emerging strategies for the treatment of PD are focused on, including early monotherapy with dopamine agonists and early combination therapy with Parkinson's disease patients and levodopa.

Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model

Moderate nigrostriatal damage which does not induce clinical parkinsonism predisposes to levodopa‐induced dyskinesias, and the severity of denervation may enhance the sensitivity to subsequent levodOPA exposures.

Dopamine agonists. Their role in the management of Parkinson's disease.